152 related articles for article (PubMed ID: 34552661)
1. Clinical Evaluation of FOXO1 as a Tumor Suppressor in Prostate Cancer.
Yang N; Wu J; Zhang T; Yang F; Shao J; He C; Qin L
Comput Math Methods Med; 2021; 2021():8773423. PubMed ID: 34552661
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.
Zeng X; Hu Z; Wang Z; Tao J; Lu T; Yang C; Lee B; Ye Z
Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):119-25. PubMed ID: 24418912
[TBL] [Abstract][Full Text] [Related]
5. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells.
Liu P; Li S; Gan L; Kao TP; Huang H
Cancer Res; 2008 Dec; 68(24):10290-9. PubMed ID: 19074897
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-30c serves as an independent biochemical recurrence predictor and potential tumor suppressor for prostate cancer.
Ling XH; Han ZD; Xia D; He HC; Jiang FN; Lin ZY; Fu X; Deng YH; Dai QS; Cai C; Chen JH; Liang YX; Zhong WD; Wu CL
Mol Biol Rep; 2014 May; 41(5):2779-88. PubMed ID: 24452717
[TBL] [Abstract][Full Text] [Related]
7. FOXO1 inhibits prostate cancer cell proliferation via suppressing E2F1 activated NPRL2 expression.
Tang Y; Jiang L; Zhao X; Hu D; Zhao G; Luo S; Du X; Tang W
Cell Biol Int; 2021 Dec; 45(12):2510-2520. PubMed ID: 34459063
[TBL] [Abstract][Full Text] [Related]
8. Long‑term exposure to leptin enhances the growth of prostate cancer cells.
Noda T; Kikugawa T; Tanji N; Miura N; Asai S; Higashiyama S; Yokoyama M
Int J Oncol; 2015 Apr; 46(4):1535-42. PubMed ID: 25625287
[TBL] [Abstract][Full Text] [Related]
9. MiR-96 expression in prostate cancer and its effect on the target gene regulation.
Bao YH; Wang Y; Liu Y; Wang S; Wu B
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(20):4548-4556. PubMed ID: 29131261
[TBL] [Abstract][Full Text] [Related]
10. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
11. miR-96 promotes cell proliferation and clonogenicity by down-regulating of FOXO1 in prostate cancer cells.
Yu JJ; Wu YX; Zhao FJ; Xia SJ
Med Oncol; 2014 Apr; 31(4):910. PubMed ID: 24633705
[TBL] [Abstract][Full Text] [Related]
12. FOXO1 promotes tumor progression by increased M2 macrophage infiltration in esophageal squamous cell carcinoma.
Wang Y; Lyu Z; Qin Y; Wang X; Sun L; Zhang Y; Gong L; Wu S; Han S; Tang Y; Jia Y; Kwong DL; Kam N; Guan XY
Theranostics; 2020; 10(25):11535-11548. PubMed ID: 33052231
[No Abstract] [Full Text] [Related]
13. LncRNA ADAMTS9-AS2 inhibits cell proliferation and decreases chemoresistance in clear cell renal cell carcinoma via the miR-27a-3p/FOXO1 axis.
Song EL; Xing L; Wang L; Song WT; Li DB; Wang Y; Gu YW; Liu MM; Ni WJ; Zhang P; Ma X; Zhang X; Yao J; Chen Y; An RH
Aging (Albany NY); 2019 Aug; 11(15):5705-5725. PubMed ID: 31400752
[TBL] [Abstract][Full Text] [Related]
14. FOXO1 inhibits Runx2 transcriptional activity and prostate cancer cell migration and invasion.
Zhang H; Pan Y; Zheng L; Choe C; Lindgren B; Jensen ED; Westendorf JJ; Cheng L; Huang H
Cancer Res; 2011 May; 71(9):3257-67. PubMed ID: 21505104
[TBL] [Abstract][Full Text] [Related]
15. Propofol inhibits proliferation and cisplatin resistance in ovarian cancer cells through regulating the microRNA‑374a/forkhead box O1 signaling axis.
Sun Y; Peng YB; Ye LL; Ma LX; Zou MY; Cheng ZG
Mol Med Rep; 2020 Mar; 21(3):1471-1480. PubMed ID: 32016462
[TBL] [Abstract][Full Text] [Related]
16. ING3 is associated with increased cell invasion and lethal outcome in ERG-negative prostate cancer patients.
Almami A; Hegazy SA; Nabbi A; Alshalalfa M; Salman A; Abou-Ouf H; Riabowol K; Bismar TA
Tumour Biol; 2016 Jul; 37(7):9731-8. PubMed ID: 26803516
[TBL] [Abstract][Full Text] [Related]
17. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion.
Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
[TBL] [Abstract][Full Text] [Related]
18. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA LINP1 promotes the malignant progression of prostate cancer by regulating p53.
Wu HF; Ren LG; Xiao JQ; Zhang Y; Mao XW; Zhou LF
Eur Rev Med Pharmacol Sci; 2018 Jul; 22(14):4467-4476. PubMed ID: 30058678
[TBL] [Abstract][Full Text] [Related]
20. Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.
Sun X; Liu Z; Yang Z; Xiao L; Wang F; He Y; Su P; Wang J; Jing B
Diagn Pathol; 2013 Dec; 8():208. PubMed ID: 24350576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
